cis-Platinum in gynecologic cancer. III. Toxicity.
The toxicity of cis-dichlorodiammineplatinum was evaluated in 41 patients who were treated for squamous cell carcinoma of the cervix or epithelial carcinoma of the ovary, with a dosage schedule of 60 mg/m2 every 3 weeks. Ototoxicity occurred in 33.3% of the patients serially tested, and anemia occurred in 48.8%. Leukopenia occurred in 29.9% and thrombocytopenia in 2.2% of courses administered. Nephrotoxicity was seen in 61% of patients as determined by evaluation of blood urea nitrogen and in 70.7% by serum creatinine elevation. Urine dipstick protein and 24 hour urinary protein determinations were evaluated. Suggestions are made in regard to the use of these determinations as a guide to modification of dose and duration of therapy.
D000328:Adult; D000368:Aged; D000740:Anemia / Q000139:chemically induced; D002277:Carcinoma / Q000188:drug therapy*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000009:adverse effects*; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D006316:Hearing Loss, High-Frequency / Q000139:chemically induced; D006801:Humans; D007668:Kidney / Q000187:drug effects; D007970:Leukopenia / Q000139:chemically induced; D008875:Middle Aged; D013921:Thrombocytopenia / Q000139:chemically induced
D002945:Cisplatin